Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaven I&g 4 Regulatory News (MAV4)

Share Price Information for Maven I&g 4 (MAV4)

Share Price is delayed by 15 minutes
Get Live Data
50.00    0.00 (0.00%)
Bid:
49.00
Ask:
51.00
Spread: 2.00 (4.082%)
Market Cap: £83.71m
MAV4 Live PriceLast checked at - London Stock Exchange

Intraday Maven I&g 4 Share Chart

Interim Management Statement - Amendment

16 Nov 2009 12:04

RNS Number : 5579C
Aberdeen Grwth Opp VCT2 PLC
16 November 2009
 



Aberdeen Growth Opportunities VCT PLC 

Correction to Interim Management Statement 

This is a correction to the previous announcement of the Interim Management Statement, which contained an error in the last line. The corrected Interim Management Statement is set out below:

1. Net Asset Value

Ordinary share net asset value (NAV) of 89.5p at 30 September 2009

S Ordinary share net asset value (NAV) of 94.2p at 30 September 2009 

The NAVs shown above are unaudited and reflect the closing bid prices of quoted securities at 30 September 2009. Unlisted companies are normally valued on a six-monthly basis and the NAVs include the Directors' valuations of unlisted investments as at 30 June 2009 adjusted for material developments within the portfolios since that date.  

2. Investments and disposals

During the quarter ended 30 September 2009the Ordinary share portfolio invested £37,000 in Adler and Allan. During the same period, disposals generated aggregate proceeds of £473,613 against cost of £457,820.

The S share portfolio invested £19,000 in the same company and during the same period, generated aggregate disposals proceeds of £165,324 against cost of £145,250.

There were no other material transactions during the period under review. 

3. Recent developments 

No further investments have been made between 30 September 2009 and the date of this statement. Since 30 September 2009, the investment in Cyclotech has been sold, realising proceeds of £688,000 and £275,000 for the Ordinary and S ordinary portfolios, compared with costs of £248,661 and £99,464 respectively. During that period, further disposals generated proceeds of £18,331 for each of the Ordinary share portfolio and the S share portfolio against similar costs.

The Board is not aware of any other events or transactions that have taken place between 30 September 2009 and the date of publication of this statement and which would have had a material impact on the financial position of the Company. 

Issued on behalf of the Board

Maven Capital Partners UK LLP, Secretary

16 November 2009

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSBFBBTMMBBBLL
Date   Source Headline
17th Apr 202512:56 pmRNSPublication of Suppl.Prospcts
7th Apr 20257:00 amRNSIssue of Equity - Replacement
4th Apr 20256:18 pmRNSIssue of Equity
2nd Apr 20255:58 pmRNSAnnual Financial Report
1st Apr 20255:05 pmRNSDirectorate Change
1st Apr 202512:59 pmRNSStatement re Offers for Subscription - Closed
27th Mar 20251:12 pmRNSDirector/PDMR Shareholding
27th Mar 20251:07 pmRNSIssue of Equity
27th Mar 202510:25 amRNSUpdate re: Offers for Subscription
18th Mar 20254:10 pmRNSTransaction in Own Shares
14th Mar 202511:58 amRNSUnaudited NAV and Proposed Final Dividend
19th Feb 202510:20 amRNSDirector/PDMR Shareholding
19th Feb 202510:19 amRNSDirector/PDMR Shareholding
19th Feb 202510:18 amRNSDirector/PDMR Shareholding
19th Feb 202510:11 amRNSIssue of Equity
28th Jan 202512:15 pmRNSStatement re Offer for Subscription
28th Jan 202510:42 amRNSIssue of Equity
24th Jan 202511:34 amRNSNet Asset Value(s)
27th Dec 20249:21 amRNSDirector Declaration
10th Dec 20244:08 pmRNSTransaction in Own Shares
26th Nov 20244:20 pmRNSNet Asset Value(s)
14th Nov 20242:55 pmRNSResult of General Meeting
18th Oct 20249:33 amRNSDirector/PDMR Shareholding
18th Oct 20249:29 amRNSIssue of Equity
15th Oct 20249:06 amRNSStatement re Dividend Investment Scheme
27th Sep 20244:31 pmRNSPublication of a Prospectus
18th Sep 202411:09 amRNSHalf-year Report
2nd Sep 20244:55 pmRNSTransaction in Own Shares
23rd Aug 20242:52 pmRNSStatement re NAV and Interim Dividend
24th May 202410:02 amRNSDirector/PDMR Shareholding
24th May 20249:58 amRNSIssue of Equity - Dividend Investment Scheme
15th May 20244:18 pmRNSTransaction in Own Shares
15th May 20242:17 pmRNSNet Asset Value - Dividend Investment Scheme
9th May 20242:35 pmRNSResult of AGM
9th May 20242:28 pmRNSUnaudited Net Asset Value
1st May 202410:08 amRNSIssue of Equity
19th Apr 202412:17 pmRNSIssue of Supplementary Prospectus
5th Apr 20243:48 pmRNSIssue of Equity
27th Mar 202410:39 amRNSIssue of Equity
25th Mar 202410:14 amRNSStatement re Offer for Subscription
19th Mar 20245:03 pmRNSTransaction in Own Shares
20th Feb 20242:48 pmRNSDividend Declaration
8th Feb 202410:33 amRNSDirector/PDMR Shareholding
8th Feb 202410:10 amRNSIssue of Equity
17th Jan 202410:03 amRNSDirector/PDMR Shareholding
17th Jan 202410:02 amRNSDirector/PDMR Shareholding
17th Jan 20249:58 amRNSIssue of Equity
15th Jan 20244:28 pmRNSUnaudited Net Value Asset
15th Nov 20235:06 pmRNSTransaction in Own Shares
9th Nov 20233:53 pmRNSNet Asset Value(s)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.